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Abstract   
Altered mitochondrial function is characteristic in the substantia nigra in Parkinson's 
disease (PD). Information about mitochondria in other brain regions such as the 
cerebral cortex is conflicting mainly because most studies have not contemplated the 
possibility of variable involvement depending on the region, stage of disease 
progression, and clinical symptoms such as the presence or absence of dementia. RT-
qPCR of 18 nuclear mRNAs encoding subunits of mitochondrial complexes and 12 
mRNAs encoding energy metabolism-related enzymes; western blotting of 
mitochondrial proteins; and analysis of enzymatic activities of complexes I, II, II, IV and 
V of the respiratory chain were assessed in frontal cortex area 8 and the angular gyrus 
of middle-aged individuals (MA), and those with incidental PD (iPD), long-lasting PD 
with parkinsonism without dementia (PD) and long-lasting PD with dementia (PDD). 
Up-regulation of several genes was found in frontal cortex area 8 in PD when 
compared with MA and in the angular gyrus in iPD when compared with MA. Marked 
down-regulation of genes encoding mitochondrial subunits and energy metabolism-
related enzymes occurs in frontal cortex but only of genes coding for energy 
metabolism-related enzymes in the angular gyrus in PDD. Significant decrease in the 
protein expression levels of several mitochondrial subunits encoded by these genes 
occurs in frontal cortex area 8 and angular gyrus in PDD. Moreover, expression of MT-
ND1 which is encoded by mitochondrial DNA is also reduced in PDD. Reduced 
enzymatic activity of complex III in frontal cortex area 8 and angular gyrus is observed 
in PD, but dramatic reduction in the activity of complexes I, II, II and IV in both regions 
characterizes PDD. Dementia in the context of PD is linked to region-specific 
deregulation of genomic genes encoding subunits of mitochondrial complexes and to 
marked reduction in the activity of mitochondrial complexes I, II, III and IV.  
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Parkinson’s disease (PD) is a chronic, progressive neurodegenerative disorder which 
in typical cases starts in the autonomic nervous system and olfactory bulb and then 
progresses to the medulla oblongata, pons and midbrain, and limbic system, eventually 
involving the neocortex several years after the beginning of symptoms. The 
classification of disease progression into six stages is based on the presence of the 
hallmark pathological lesions and is useful to explain clinical manifestations which 
parallel neuropathological lesions in typical cases, at least at the first and middle 
stages of the disease (8, 14, 15, 27). Hallmark pathological lesions are Lewy bodies 
and neurites (LB inclusions) composed of abnormal α-synuclein (28).   
Altered mitochondrial function mainly characterized by reduced complex I activity and 
increased oxidative damage is well documented in the substantia nigra in PD where 
dopaminergic neurons projecting to the striatum degenerate and LB inclusions are 
abundant. This is accompanied by oxidative damage (41). Combined phosphorus and 
proton magnetic resonance spectroscopic imaging have also shown mitochondrial 
dysfunction in midbrain and putamen in PD (26). Mitochondrial degeneration and 
oxidation of several mitochondrial-associated proteins have also been observed in α-
synuclein transgenic mice used as a model of PD (32, 38).   
Oxidative damage is not restricted to the substantia nigra and striatum in PD. 
Increased expression of oxidative stress markers and altered oxidative responses 
occur in the frontal cortex (1, 25, 34, 39). This is further supported by the identification 
in the frontal cortex of proteins which are damaged as a result of oxidation, including α-
synuclein, β-synuclein, UCHL1, SOD1, SOD2 and DJ-1 (9, 10, 11, 12, 13, 33). 
Moreover, several key proteins are targets of oxidative damage in the frontal cortex 
even at very early stages of PD, such as aldolase A, enolase 1 and glyceraldehyde 
dehydrogenase (GAPDH), all of them involved in glycolysis and energy metabolism  
(23).   
Oxidative damage and disassembly of complex I subunits, functional impairment of 
complex I activity and adaptive responses are found in the frontal cortex at advanced 
stages of PD, in some cases in patients who probably suffered from dementia (29, 36, 
37), and in PD plus dementia (22). Altered mitochondrial function is also observed in 
dementia with Lewy bodies (DLB) (36). However, little information is available 
regarding mitochondrial alterations in the cerebral cortex with disease progression 
from early pre-motor stages of PD to advanced stages without and with associated 
dementia.   
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Previous studies have shown reduced metabolism, as revealed with [(18)F]-
fluorodeoxyglucose Positron Emission Tomography (PET), in the frontal cortex, and 
progression to the angular gyrus, orbital cortex, posterior cingulus and occipital lobes in 
PD patients with cognitive impairment and dementia  (5, 21, 31). 
Based on these data, the objective of the present study was to characterize the 
involvement of mitochondria in the cerebral cortex in PD post-mortem samples in three 
groups: iPD, cases without parkinsonian symptoms categorized neuropathologically as 
stages 3 and 4 and dying of fatal concurrent events that disrupted life expectancies; 
PD, cases with a long history of parkinsonism and subjected to anti-parkinsonian 
therapy for several years without dementia, categorized neuropathologically as stages 
5 and 6 without dementia; and PDD, cases with long lasting parkinsonism who 
developed dementia after several years from the beginning of the parkinsonian 
symptoms, categorized neuropathologically as stage 6. Two regions, frontal cortex 
area 8 and the angular gyrus, both progressively involved along with disease duration, 
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Material and methods 
 
Human cases 
Brain tissue was obtained from the Institute of Neuropathology HUB-ICO-IDIBELL 
Biobank following the guidelines of Spanish legislation on this matter and the approval 
of the local ethics committee. Processing of brain tissue has been detailed elsewhere 
(40). The post-mortem interval between death and tissue processing was between 2 
and 21h 45min. One hemisphere was immediately cut in coronal sections, 1cm thick, 
and selected areas of the encephalon were rapidly dissected, frozen on metal plates 
over dry ice, placed in individual air-tight plastic bags and stored at -80ºC until use for 
biochemical studies. The other hemisphere was fixed by immersion in 4% buffered 
formalin for 3 weeks for morphological studies. Neuropathological diagnosis in all 
cases was based on the routine study of 20 selected de-waxed paraffin sections 
comprising different regions of the cerebral cortex, diencephalon, thalamus, brain stem 
and cerebellum, which were stained with haematoxylin and eosin, and Klüver-Barrera, 
and for immunohistochemistry for microglia, glial fibrillary acidic protein, β-amyloid, 
phosphorylated tau (clone AT8), α-synuclein, TDP-43, ubiquitin and p62. 
Neuropathological staging of PD was based on the classification of Braak et al (8). 
Only typical cases according to the Braak classification—those with progressive 
involvement of the medulla oblongata, pons, substantia nigra, limbic system and 
neocortex—were included. Cases with combined pathologies (i.e., Alzheimer’s disease 
excepting sporadic AD-related pathology stages I-II/0-A (7), tauopathy, cerebrovascular 
diseases, and metabolic syndrome) were excluded from the present study. Middle-
aged cases (MA) (n=34, 23 men, 11 women; age, 65.4 ± 14.8 years) had not suffered 
from neurologic, psychiatric, or metabolic diseases (including metabolic syndrome), 
and did not have abnormalities in the neuropathological examination excepting 
sporadic AD stages I-II/0-A. PD cases with more advanced stages of sAD-related 
pathology were not considered in the present series to avoid overlap between PD and 
AD in the frontal cortex and angular gyrus.   
Clinically, iPD cases (n=15, 12 men, 3 women; age 69.6 ± 8.6) at stages 3 and 4 were 
apparently asymptomatic and were identified at the time of the post-mortem 
neuropathological examination. PD cases (n=20, 11 men, 9 women; age, 78.5 ± 4.4 
years) at stages 5 and 6 had suffered from parkinsonism and had received treatment 
during the duration of the disease but did not have dementia. PDD cases (n = 4 men, 
age 80.5 ± 3.4 years), all of them stage 6, had suffered from parkinsonism for more 
than ten years and later developed dementia. The causes of death in these cases were 
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unrelated events that reduced survival expectancy, including cardiac infarction, 
disseminated carcinoma and infectious diseases.   
Two cortical regions were examined: frontal cortex area 8 and the angular gyrus. A 
summary of all the cases is shown in Table I. Not all regions were assessed in every 
case due to the limited availability of tissues. This has reduced the possibility to study 
certain parameters as for example activity of mitochondrial complexes in iPD.  
 
RNA purification 
Purification of RNA from right frontal cortex area 8 and the angular gyrus was carried 
out using RNeasy Lipid Tissue Mini Kit (Qiagen, Hilden, Germany) following the 
protocol provided by the manufacturer and performing the optional DNase digest to 
avoid extraction and later amplification of genomic DNA. The concentration of each 
sample was obtained from A260 measurements with a NanoDrop 2000 
spectrophotometer (Thermo Scientific, Waltham, MA, USA). RNA integrity was tested 
using the Agilent 2100 BioAnalyzer (Agilent, Santa Clara, CA, USA). Values of RNA 
integrity number (RIN) varied from 6.4 to 8.8 (Table I). Post-mortem delay had no effect 
on RIN values in the present series (Table I). 
 
Retrotranscription reaction 
Retrotranscription reaction of RNA samples selected based on their RIN values was 
carried out with the High-Capacity cDNA Archive kit (Applied Biosystems, Foster City, 
CA, USA) following the guidelines provided by the manufacturer, and using Gene 
Amp® 9700 PCR System thermocycler (Applied Biosystems). A parallel reaction for 




Real-time quantitative PCR (RT-qPCR) assays were conducted in duplicate on 
1,000ηg of cDNA samples obtained from the retrotranscription reaction, diluted 1:20 in 
384-well optical plates (Kisker Biotech, Steinfurt, GE) utilizing the ABI Prism 7900 HT 
Sequence Detection System (Applied Biosystems). Parallel amplification reactions 
were carried out using 20x TaqMan Gene Expression Assays and 2x TaqMan 
Universal PCR Master Mix (Applied Biosystems). TaqMan probes used in the study are 
shown in Table II.  
Parallel assays for each sample were carried out using probes for β-glucuronidase 
(GUS-β) and X-prolyl aminopeptidase P1 (XPNPEP1) for normalization.  The reactions 
were performed using the following parameters: 50ºC for 2 min, 95ºC for 10 min, 40 
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cycles at 95ºC for 15 s, and 60ºC for 1 min. TaqMan PCR data were captured using the 
Sequence Detection Software (SDS version 2.2, Applied Biosystems). Subsequently, 
threshold cycle (CT) data for each sample were analyzed with the double delta CT 
(∆∆CT) method. First, delta CT (∆CT) values were calculated as the normalized CT 
values for each target gene in relation to the endogenous controls GUS-β and 
XPNPEP1. These housekeeping genes were selected because they show no 
modifications in several neurodegenerative diseases in human post-mortem brain 
tissue (2, 16). A similar pattern was observed using GUS-β and XPNPEP1 for 
normalization (data not shown). GUS-β was selected as a housekeeping gene for 
representation. Finally, ∆∆CT values were obtained with the ∆CT of each sample 
minus the mean ∆CT of the population of control samples (calibrator samples). The 
fold-change was determined using the equation 2-∆∆CT (20). 
 
Statistical analysis for RT-qPCR 
The normality of distribution of the mean fold-change values obtained by RT-qPCR for 
every region and stage between controls and PD cases was analyzed with the 
Kolmogorov-Smirnov test. The non-parametric Mann-Whitney test was performed to 
compare each group when the samples did not follow a normal distribution whereas the 
unpaired Student’s T-test was used for normal variables. Statistical analysis was 
performed with GraphPad Prism version 5.01 (La Jolla, CA, USA) and Statgraphics 
Statistical Analysis and Data Visualization Software version 5.1 (Warrenton, VA, USA). 
Differences between groups were considered statistically significant at P-values: *p < 
0.05, **p < 0.01 and ***p < 0.001. 
 
Gel electrophoresis and western blotting from total homogenates 
0.1g of sample brain tissue from frontal cortex area 8 and the angular gyrus (see Table 
I) were homogenized with a glass homogenizer in Mila lysis buffer (0.5M Tris at pH 7.4 
containing 0.5 methylenediaminetetraacetic acid at pH 8.0, 5M NaCl, 0.5% Na 
doxicholic, 0.5% Nonidet P-40, 1mM phenylmethylsulfonyl fluoride, bi-distilled water, 
protease and phosphatase inhibitor cocktails) (Roche Molecular Systems, Pleasanton, 
CA, USA), and then centrifuged for 15 min at 13,000rpm at 4°C (Ultracentrifuge 
Beckman with 70Ti rotor, CA, USA). Protein concentration was measured with a 
SmartspectTMplus spectrophotometer (Bio-Rad, CA, USA) using the Bradford method 
(Merck, Darmstadt, Germany). Samples containing 20µg of protein and the standard 
Precision Plus ProteinTM Dual Color (Bio-Rad) were loaded onto 10-15% acrylamide 
gels. Proteins were separated in sodium dodecylsulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) and electrophoretically transferred to nitrocellulose 
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membranes using the Trans-Blot®TurboTM transfer system (Bio-Rad) at 
200mA/membrane for 40 min. Non-specific bindings were blocked by incubation in 5% 
milk in Tris-buffered saline (TBS) containing 0.1% Tween for 1 h at room temperature. 
After washing, the membranes were incubated at 4°C overnight with each of the 
following antibodies in TBS containing 5% albumin and 0.1% Tween: monoclonal 
antibody anti-cytochrome c oxidase subunit VIIa polypeptide 2 like, COX7A2L (1:800; 
66062-1-Ig, Proteintech, Chicago, IL, USA); polyclonal antibodies anti-NADH 
dehydrogenase (ubiquinone) 1 alpha subcomplex 7, NDUFA7 (1:100; 15300-1-AP, 
Proteintech); anti-NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 10, 
NDUFA10 (1:2,000; GTX114572, GeneTex, CA, USA); anti-NADH dehydrogenase 
(ubiquinone) 1 beta subcomplex 10, NDUFB10 (1:3,000; 15589-1-AP, Proteintech), 
anti-NADH dehydrogenase (ubiquinone) Fe-S protein 8, NDUFS8 (1:1,000; 
GTX114119, GeneTex) and anti-MT-ND1: mitochondrial encoded NADH 
dehydrogenase 1 (1:1,000; ab181848, Abcam, Cambridge, UK). Finally, monoclonal 
antibody anti-β-actin (1:30,000, A5316; Sigma-Aldrich, St. Louis, MO, USA) was blotted 
for the control of protein loading. Afterwards, the membranes were incubated for 1 h 
with the appropriate HRP-conjugated secondary antibody (1:2,000, Dako, Glostrup, 
Denmark), and the immune-complexes were revealed with a chemiluminescence 
reagent (ECL, Amersham, GE Healthcare, Buckinghamshire, UK). Densitometry of 
western blot bands was assessed with the TotalLab program (TotalLab Quant, 
Newcastle, UK) and subsequently analyzed with Student’s T-test using the 
Statgraphics Statistical Analysis and Data Visualization Software version 5.1 (VA, 
USA); differences were considered statistically significant with p-values: *p < 0.05; **p 
< 0.01; ***p < 0.001. 
 
Isolation of mitochondrial-enriched fractions from human brain tissue 
Mitochondria were extracted from frozen human brain tissue (100mg) under ice-cold 
conditions. Tissues were minced in ice-cold isolation buffer (IB) containing 0.25M 
sucrose, 10mmol/l Tris and 0.5mmol/l EDTA, pH 7.4, and then homogenized and 
centrifuged at 1,000xg for 10 min. Samples were homogenized with a micro-pestle 
using 10 volumes of buffer per mg of tissue and centrifuged at 1,000xg for 10 min at 
4ºC. The supernatant (S1) was conserved. The pellet was washed with 2 volumes of IB 
and centrifuged again under the same conditions. This last supernatant (S2) was 
combined with S1. Centrifugation at 10,000xg for 10 min at 4ºC resulted in the 
mitochondria-enriched pellet. The supernatant (S3) was discarded and the pellet was 
washed with 2 volume of IB. The pellet was finally re-suspended in 1 volume of IB and 
stored at -80ºC. Protein concentration was measured by SmartspectTMplus 
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spectrophotometer (Bio-Rad, CA, USA) using the Bradford method (Merck, Darmstadt, 
Germany). Sonication was performed as described (30). Optimal sonication conditions 
were 10 sec 8 times with minimal intervals at 3W (44). The mitochondrial enrichment 
was used for mitochondrial enzymatic activities and for western blotting using anti-α-
synuclein polyclonal antibody (1:10,000; A5316, Chemicon, Darmstadt, Germany); anti-
neuroketal (NKT, 1:1,000; AB5611, Chemicon); and anti N-Tyrosine (N-Tyr, 1:500, 32-
1900, Thermo Fisher – Invitrogen, Carlsbad, CA, USA). Differences in protein loading 
were corrected with anti-β-actin (1:30,000, A5316; Sigma-Aldrich); mitochondrial levels 
were assessed with anti-oxidative phosphorylation-ATP5A (1:10,000; MS601, 
Mitoscience, Eugene, OR, USA). 
 
Mitochondrial enzymatic activities  
The individual activities of mitochondrial complexes I, II, III, IV and V were analysed 
using commercial kits following the manufacturers’ instructions (Mitochondrial complex 
I, II, IV and V: Novagen, Merck Biosciences, Darmstadt, Germany; Mitochondrial 
complex III: MyBiosource, CA, USA). 25µg of mitochondria was loaded into each well. 
Activity of citrate synthase was evaluated following validated protocols (42) with slight 
modifications. The activity of citrate synthase was determined as the rate of reduction 
of DTNB (5’, 5’-dithiobis (2-nitrobenzoic acid)) to thionitrobenzoic acid at 412nm. For 
this purpose, 25µg of mitochondria was added to a 1ml mixture containing 500µl of Tris 
(200mM, pH8.0) with Triton X-100 (0.2% (vol/vol)), 100µl of DTNB, and 30µl of 10mM 
Acetyl CoA; the final volume was adjusted to 950µl with distilled water. The reaction 
was started by the addition of 50µl of 10mM oxalacetic acid. The increase in 
absorbance at 412 nm was read for 3 min at room temperature with a DU® 
800UV/Visible spectrophotometer (Beckman Coulter, CA, USA) in 1ml polystyrene or 
methacrylate cuvettes. 
 
Statistical analysis for mitochondrial activities 
The enzymatic activities for each mitochondrial complex were expressed as a rate of 
nmol/min per mg of mitochondrial protein per protein concentration normalized with the 
mitochondrial complex activity rate of citrate synthase activity. Data were presented as 
mean ± standard error of the mean (SEM) in all the experiments. All the data were 
analyzed with Student’s T-test using GraphPad Prism version 5.01 (La Jolla, CA, USA) 
and Statgraphics Statistical Analysis and Data Visualization Software version 5.1 
(Warrenton, VA, USA). In all experimental procedures the significance level was set at 
*p < 0.05; **p < 0.01; ***p < 0.001. 
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mRNA expression levels of selected mitochondrial subunits in frontal cortex 
area 8  
No differences in the expression levels of the majority of assessed genes were 
observed in iPD when compared with MA excepting NDUFB3 and ATP5H, which 
decreased in iPD (Table III). However, a significant increase in the expression of 
NDUFA7, NDUFA10, NDUFB7, NDUFB10, NUDFS8, SDHB, UQCR11, COX7A2L and 
ATP5G2 mRNAs was found in PD compared with MA individuals. NDUFA2, NDUFA7, 
NDUFA10, NDUFB3, ATP5G2, ATP5H and ATP5L were significantly increased when 
comparing PD with iPD (Table III). Two genes deregulated in arrays, NDUFS7 and 
ATP5G2, were not validated by RT-qPCR. 
In contrast to PD, a marked decrease in the expression of genes encoding several 
subunits of mitochondrial complexes was found in PDD. Significant down-regulation in 
SDHB, COX7C and ATP5G2 was observed when comparing MA cases to PDD. More 
dramatic change was recognized when comparing PD and PDD, as the expression of 
twelve of the eighteen genes analysed was significantly decreased in PDD, including  
NDUFA7, NDUFA10, NDUFB7, NDUFB10, NDUFS8, SDHB, UQCRB, COX7A2L, 
COX7C, ATP5G2, ATP5L and ATP5O (Table III). Values were similar using GUS-β 
and XPNPEP1 for normalization but GUS-β was selected as housekeeping for 
representation. 
 
mRNA expression levels of energy metabolism-related enzymes in frontal cortex 
area 8  
ATP2B4, AT6V0A1 and TOMM40 were significantly decreased and ATP4A increased 
in iPD when compared with MA. ZNF642 was up-regulated in PD when compared with 
MA. However, the expression levels of ATP2B4, ATP4A, ATP6V0A1, ATP6VOB, 
TOMM40 and ZNF642 mRNAs were significantly increased in PD when compared with 
iPD (Table III).  
In contrast to PD cases, a marked decrease in the expression of genes related to 
energy metabolism was found in PDD. ATP2B4, ATP6V0B, FAM82A2 and LHPP 
mRNA expression was significantly reduced in PDD when compared with MA. 
ATP2B4, ATP6V0A1, ATP6V0B, ATP6V1H and ZNF642 were down-regulated in PDD 
in comparison with PD (Table IV).  
Detailed quantitative data are shown in Supplementary Table I. 
 
mRNA expression levels of selected mitochondrial subunits in the angular gyrus 
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NDUFA7, NDUFA10, NDUFB10, NDUFS7, UQCRB, UQCR11, COX7A2L, ATP5D and 
ATP5G2 mRNA expression was up-regulated in iPD when compared with MA (Table 
IV). However, only NDUFA10 mRNA levels were increased when comparing PD with 
MA cases (Table IV). This was due to a shift between iPD and PD as NDUFA7, 
NDUFB10, NDUFS7, NDUFS8 and COX7A2L were significantly decreased in PD when 
compared with iPD (Table IV).  
Interestingly, no apparent changes were found in PDD when compared with MA cases. 
However, NDUFA2, NDUFA7, NDUFA10, NDUFB10, NDUFS7, SDHB, UQCR11, 
COX7A2L, ATP5G2 and AT5O were significantly down-regulated in PDD when 
compared with iPD. COX7A2L mRNA was decreased in PDD when compared with PD 
(Table IV).  
Detailed quantitative data are shown in Supplementary Table I. 
 
mRNA expression levels of energy metabolism-related enzymes in the angular 
gyrus 
Two genes out of twelve, ATP6V0B and ATP6V1H1, encoding energy metabolism-
related enzymes assessed in the present study were up-regulated in iPD when 
compared with PD (Table IV). No significant differences were observed in PD when 
compared with MA. However, ATP6V0B and ATP6V1H1 were significantly reduced in 
PD when compared with iPD (Table IV). 
Gene expression was markedly decreased in PDD cases when compared with MA, iPD 
and PD. ATP2B4, FAM82A2 and LHPP were down-regulated when comparing MA with 
PDD. ATP2B4, ATP6V0B, ATP6V1H, SLC6A6 and ZNF642 were decreased in PDD 
cases compared with iPD. ATP2B4, ATP6V1H, FAM82A2 and LHPP were significantly 
down-regulated in PDD in comparison with PD (Table IV). 
 
Protein expression levels of selected subunits of mitochondrial complexes in 
frontal cortex area 8 and angular gyrus in iPD, PD and PDD  
Western blot was carried out using antibodies to proteins NADH dehydrogenase 
(ubiquinone) 1 alpha sub-complex, 7 (encoded by NDUFA7), NADH dehydrogenase 
(ubiquinone) 1 alpha sub-complex, 10 (encoded by NDUFA10), NADH dehydrogenase 
(ubiquinone) 1 beta sub-complex 10 (encoded by NDUFB10), NADH dehydrogenase 
(ubiquinone) Fe-S protein 8 (encoded by NDUFS8) and cytochrome c oxidase subunit 
VIIa polypeptide 2 (encoded by COX7A2L). Expression levels were normalized with β-
actin and VDAC. 
NDUFA7 was significantly decreased in the frontal cortex in iPD in comparison with MA 
cases, but significantly increased in PD when compared with iPD. NDUFS8 was 
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significantly increased in PD when compared to MA (Figure 1A). NDUFA7 and 
NDUFS8 protein levels matched corresponding mRNA values (Table III). No variations 
of NDUFA10, NDUFB10 and COX7A2L protein levels were observed in the frontal 
cortex in iPD or PD compared with MA (Figure 1A). However, significant decrease in 
the expression levels of proteins NDUFA7, NDUFB10, NDUFS8 and COX7A2L was 
found in frontal cortex area 8 in PDD cases (Fig. 1A) matching with values of mRNA 
expression (Table III).   
No modifications in NDUFA7, NDUFB10 and NDUFS8 protein expression levels were 
seen in the angular gyrus in iPD and PD. However, NDUFA10 was significantly 
increased in PD when compared with MA, and COX7A2L was significantly increased in 
iPD but not in PD when compared with MA (Figure 1B). NDUFA10, NDUFB10 and 
COX7A2L protein levels matched corresponding mRNA values obtained with RT-qPCR 
(Table IV). Significant decrease in NDUFA7, NDUFA10, NDUFB10, NDUFS8 and 
COX7A2L protein levels occurred in the angular gyris un PDD (Fig. 1B) matching with 
corresponding mRNA levels (Table IV). 
Results were similar when using β-actin and VDAC for normalisation (Fig 1).    
 
Protein expression levels of MT-ND1 in frontal cortex area 8 and angular gyrus in 
iPD, PD and PDD  
MT-ND1 was assessed to test the expression level of a subunit encoded by 
mitochondrial DNA. Other antibodies tested to analyze the expression of mitochondrial 
subunits did not work in our hands.    
Significant MT-ND1 reduction was observed in frontal cortex in iPD and PDD when 
compared with MA using β-actin or VDAC for normalization (Fig. 2).  Lack of significant 
differences in PD 5-6 when compared with the other groups was related to large 
individual variations in the expression levels in this group.  
Reduced MT-ND1 was also observed in the angular gyrus when comparing PDD with 
MA using VDAC but not β-actin for normalization (Fig. 2).  
 
Activity of mitochondrial complexes I, II, III, IV and V in frontal cortex area 8 and 
angular gyrus in PD  
No modifications in the activity of complexes I, II and V were observed in frontal cortex 
area 8 in PD normalized with citrate synthase activity (Figure 3A). Activity of complex III 
was decreased in PD while complex IV showed the opposite pattern, with an increase 
in the same stages of the pathology; p-values <0.05 (Figure 3A).  
Enzyme activities in the angular gyrus showed an equal pattern when comparing MA 
cases to PD with no variations except in complex III, which showed reduced activity 
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with a significant p-value <0.05 (Figure 3B). All the enzymatic activities of mitochondrial 
complexes were corrected for citrate synthase activity.  
 
Activity of mitochondrial complexes I, II, III, IV and V in frontal cortex area 8 and 
angular gyrus in PDD  
Mitochondrial enzymatic activities of complexes I, II, III and IV were markedly reduced 
in frontal cortex area 8 in PDD when compared with MA individuals (p-values between 
0.05 and 0.01) (Figure 4A). 
Similar alterations were seen in the angular gyrus. A marked reduction in the activity of 
complexes I, II, II and IV was found in PDD when compared with MA (p-values 
between 0.05 and 0.01) (Figure 4B).  
 
α-synuclein protein expression and NKT protein adduct levels in mitochondrial-
enriched fractions 
Protein expression levels of α-synuclein were analysed with western blotting in 
mitochondrial-enriched fractions of frontal cortex area 8 in MA and PD cases. Levels of 
monomeric α-synuclein (17 kDa) were similar in MA and PD cases. However, protein 
levels of oligomeric forms of 37 kDa and 50 kDa of α-synuclein were significantly 
increased in PD (p<0.05) when compared with MA (Fig. 5A). β-actin was used as a 
control of protein loading, and ATP5A as a marker of mitochondria, revealing no 
differences between MA and PD.  
Levels of neuroketal (NKT) protein adducts were significantly increased (p<0.01) in 
mitochondrial-enriched fractions of frontal cortex area 8 in PD when compared with MA 
cases (Fig. 5B). Levels of N-Tyrosine were similar in mitochondrial-enriched fractions 
of frontal cortex area 8 in PD when compared with MA cases (Fig. 5C).  
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Molecular studies in human post-mortem brain tissue have revealed that metabolic 
alterations precede neurological symptoms in most neurodegenerative diseases by 
many years. In particular, multiple defects converge, at least in the frontal cortex, at 
early stages of PD even in the absence of deficits in cortical function (17, 18).  
Expression of selected genomic genes encoding mitochondrial protein subunits of the 
respiratory chain complexes and the activities of complex I, II, III, IV and V was 
analyzed in frontal cortex area 8 and the angular gyrus in neuropathologically-verified 
iPD, PD and PDD cases. The selection of genes was based on parallel studies carried 
out in several neurodegenerative diseases with abnormal protein aggregates in which 
the same genes were analyzed including several subunits of complex I-V. Although this 
approach does not cover all the mitochondrial subunits, it serves to analyze 
comparative studies among diseases with abnormal protein aggregates in old age. This 
aspect is founded on the hypothesis that although mitochondria are vulnerable in 
various neurodegenerative diseases, the alteration of subunits and susceptibility of 
complexes is disease-dependent. The study of mitochondria is accompanied by gene 
expression analysis of other energy metabolism-related enzymes.  
Previous studies have shown reduced metabolism, as revealed with [(18)F]-
fluorodeoxyglucose Positron Emission Tomography (PET), in the frontal cortex, and 
progression to the angular gyrus, orbital cortex, posterior cingulus and occipital lobes in 
PD patients with mild cognitive impairment (5, 21, 31). Neuroimaging analyses have 
also suggested that cortical hypometabolism is present even at early stages of PD (4, 
6). Interestingly, hypometabolism is followed by cortical atrophy in the same areas in 
PDD (24).   
Present findings show regional differences in the expression of several nuclear genes 
encoding subunits of mitochondrial complexes and energy metabolism-related 
enzymes. Most important changes in frontal cortex area 8 are manifested by up-
regulation of genes encoding subunits of complexes I, II, III, IV and V in PD when 
compared with MA, and energy-metabolism related enzymes when comparing iPD with 
PD. In contrast, gene up-regulation in the angular gyrus occurs in iPD when compared 
with MA, and values mostly return to normal levels in PD. Protein levels of selected 
subunits parallel values of corresponding gene expression. Therefore, altered 
regulation of genes and proteins related to mitochondria and energy metabolism is an 
early region-dependent event in the frontal cortex area 8 and angular gyrus in PD. 
However, these alterations have only a moderate impact on the activity of 
mitochondrial complexes, as only complex III activity is reduced in the frontal cortex 
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and angular gyrus in PD. These changes do not contradict the marked impairment of 
mitochondria biogenesis, altered mRNA expression, deregulation of several 
microRNAs predicted to interact with complex I regulators, and alterations of protein 
levels which also occur in frontal cortex in PD (43). Rather, they are consistent with a 
scenario in which several molecules, including mitochondrial membrane proteins, ion 
channels and mitochondrial subunits, are altered to determinate thresholds until they 
produce altered activity. In this line, oxidative damaged of certain protein subunits, 
rather than reduced protein levels, can jeopardize mitochondrial function in PD (29).    
Dramatic changes occur in PDD as the expression of genes encoding mitochondrial 
subunits and energy-related enzymes is markedly down-regulated in frontal cortex area 
8, whereas down-regulation mainly involves energy-related enzymes in the angular 
gyrus in PDD when compared with PD. Nevertheless, protein expression of several 
mitochondrial subunits falls in frontal cortex and angular gyrus in PDD. Differences 
between mRNA and protein expression levels are not uncommon as protein translation 
is modulated by several molecules mainly non-coding RNAs. Changes in protein 
expression might be the result of mitochondrial loss although decreased protein values 
are similarly affected when using β-actin and VDAC for normalization. Reduced mRNA 
expression here observed corresponds to nuclear-encoded mRNAs therefore indicating 
that, at least, part of mitochondrial dysfunction in PD is linked to abnormalities in 
nuclear mRNA processing of genes encoding subunits of mitochondrial complexes. 
Reduced complex I activity has been reported in frontal cortex area 8 at advanced 
stages of PD in which unfortunately no clinical information about their cognitive status 
was available (29, 35, 36, 37). More focused studies on PD and dementia have shown 
reduced complex I activity only in PDD, and not in PD (22). The present observations in 
PDD are in the same line although decreased activity affects not only complex I but 
also complexes I, II, III and IV. Moreover, reduced mitochondrial activity is not 
restricted to the frontal cortex; the angular gyrus, the other region assessed in the 
present study, has also mitochondrial functional deficiencies. Curiously, the expression 
of nuclear genes encoding subunits of mitochondrial complexes is dramatically reduced 
in the frontal cortex area 8, but not in the angular gyrus, in PDD, thus indicating 
regional differences in the transcription of nuclear genes encoding mitochondrial 
subunits between frontal cortex and angular gyrus.   
Reduced mitochondrial DNA levels have been reported in the prefrontal cortex in PDD 
but not in PD, thus suggesting that primary alterations in mitochondrial DNA are 
causative of mitochondrial dysfunction and dementia in PDD (22). However, the 
expression of mitochondrial subunits encoded by mitochondrial DNA was not examined 
in that study. Present finds have shown decreased expression of MT-ND1 in frontal 
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cortex and angular gyrus in PDD cases when compared with MA. Moreover, MT-ND1 
expression appears to be significantly reduced in frontal cortex at least in some iPD 
cases. Since modifications in DNA content can vary in different mitochondria, and differ 
from one cell to another, it can be suggested that the expression levels of other 
subunits encoded by mitochondrial DNA can be also altered in PD.    
Present findings have also shown the presence of α-synuclein oligomers in 
mitochondrial-enriched fractions in PD thus suggesting that local oligomers may affect 
mitochondrial function. In this line, abnormal α-synuclein oligomers are detected in the 
nuclear fractions of FACS-isolated neurons in frontal cortex in PD in association with 
marked alterations in the expression of genes and nuclear proteins involved in the 
machinery of protein synthesis (19). Moreover, increased levels of NKT protein adducts 
in mitochondrial-enriched fractions point to increased protein damage derived from 
docosahexaenoic acid peroxidation end-products (DHA; C22:6 ω3) (3).  
These data together with previous studies suggest that the scenario is not simple as 
mitochondrial dysfunction in cerebral cortex and perhaps in other regions in PD may be 
due to the combination of altered nuclear and mitochondrial transcription which in turn 
may depend on the vulnerability of genomic and mitochondrial DNA, and in post-
translational modifications of mitochondrial subunits due to oxidative damage.  
Finally, although the presence of Lewy bodies and neurites as revealed by PD stages 
seems to play a role in the progression of altered transcription and protein expression 
linked to mitochondria and energy metabolism, dementia is only observed at PD stage 
6 in combination with failure in the activity of complexes I, II, III and IV of the respiratory 
chain in frontal cortex area 8 and angular gyrus.   
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ATP2B3: ATPase, Ca++ transporting, plasma membrane 3 
ATP2B4: ATPase, Ca++ transporting, plasma membrane 4 
ATP4A: ATPase, H+/K+ exchanging, alpha polypeptide 
ATP5D: ATP synthase, H+ transporting, mitochondrial F1 complex, delta subunit 
ATP5G2: ATP synthase, H+ transporting, mitochondrial Fo complex, subunit C2 
(subunit 9) 
ATP5H: ATP synthase, H+ transporting, mitochondrial Fo complex, subunit d 
ATP5L: ATP synthase, H+ transporting, mitochondrial Fo complex, subunit G 
ATP5O: ATP synthase, H+ transporting, mitochondrial F1 complex, O subunit 
ATP6V0A1: ATPase, H+ transporting, lysosomal V0 subunit a1 
ATP6V0B: ATPase, H+ transporting, lysosomal 21kDa, V0 subunit b 
ATP6V1H1: ATPase, H+ transporting, lysosomal 50/57kDa, V1 subunit H 
COX7A2L: cytochrome c oxidase subunit VIIa polypeptide 2 like 
COX7C: cytochrome c oxidase subunit VIIc 
DHA: docosahexaenoic acid (C22:6 ω3) 
FAM82A2: family with sequence similarity 82, member A2 
GUS-B: B-glucuronidase 
LHPP: phospholysine phosphohistidine inorganic pyrophosphate phosphatase 
MT-ND1: mitochondrial encoded NADH dehydrogenase 1 
NDUFA2: NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 2, 8kDa 
NDUFA7: NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 7, 14.5kDa 
NDUFA10: NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 10, 42kDa 
NDUFB3: NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 3, 12kDa 
NDUFB7: NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 7, 18kDa 
NDUFB10: NADH dehydrogenase (ubiquinone) 1 beta subcomplex 10, 22kDa 
NDUFS7: NADH dehydrogenase (ubiquinone) Fe-S protein 7, 20kDa (NADH-
coenzyme Q reductase) 
NDUFS8: NADH dehydrogenase (ubiquinone) Fe-S protein 8, 23kDa (NADH-
coenzyme Q reductase) 
NKT: neuroketal  
N-Tyr: nitro-tyrosine 
SDHB: succinate dehydrogenase complex, subunit B, iron sulfur (Ip) 
SLC6A6: solute carrier family 6 (neurotransmitter transporter, taurine), member 6 
SLC25A31: solute carrier family 25 (mitochondrial carrier; adenine nucleotide 
translocator), member 31 
TOMM40: translocase of outer mitochondrial membrane 40 homolog (yeast) 
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UQCRB: ubiquinol-cytochrome c reductase binding protein 
UQCR11: ubiquinol-cytochrome c reductase, complex III subunit XI 
XPNPEP1: X-prolyl aminopeptidase P1 
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Table I: Summary of cases used for mRNA expression, western blot and mitochondrial 
activity studies in the frontal cortex area 8 (FC) and in the angular gyrus (AG). PD: 
Parkinson’s disease, 0: Cases 1-34 are middle-aged individuals with no neurological 
symptoms and without neuropathological evidence of disease; iPD: incidental PD 
(cases 35-49, stages 3, 4 of Braak without clinical symptoms of parkinsonism), PD: 
treated parkinsonism of long duration (cases 50-69, stages 5, 6 of Braak); PDD: PD 
with dementia (cases 70-73, stage 6 with long-lasting parkinsonism and late 
development of dementia); M: male; F: female; Age in years; post-mortem delay in 
hours and minutes; RIN: values of RNA integrity number; WB: western blot; MA: 
mitochondrial activity complexes.  
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Nº CASE PD GENDER AGE PM DELAY RIN FC RIN AG WB FC WB AG MA FC MA AG
1 0 MALE 64 8h 30m 7.7 7.7 X X - -
2 0 MALE 56 5h 7.8 6.8 X X X -
3 0 MALE 67 5h 7.4 6.7 X X - -
4 0 MALE 62 3h 8 6.8 X X - -
5 0 MALE 52 4h 40m 8.1 6.7 X X - -
6 0 MALE 30 4h 10m 8.4 - X - - -
7 0 MALE 53 3h 8.8 6.6 X X X -
8 0 FEMALE 49 7h 8.2 - X - - -
9 0 FEMALE 75 3h 7.7 8.7 X X - -
10 0 FEMALE 46 9h 35m 6.8 6.8 X X - -
11 0 FEMALE 86 4h 15m 8.1 - X - - -
12 0 FEMALE 79 3h 35m 7.7 - X - - -
13 0 FEMALE 79 6h 25m 7.8 - X - - -
14 0 FEMALE 77 3h 15m 7 - X - - -
15 0 FEMALE 76 5h 45m 8.3 - - - - -
16 0 FEMALE 71 8h 30m 7.4 - - - - -
17 0 MALE 56 5h 6.9 - - X - X
18 0 FEMALE 78 12h 6.5 - - X - X
19 0 MALE 71 3h - - - X - X
20 0 MALE 103 3h - - - X - X
21 0 MALE 59 4h 15m - - - - - X
22 0 MALE 61 4h 30m - - - - - X
23 0 MALE 70 13h - - - - X -
24 0 MALE 39 9h 15m - - - - X -
25 0 FEMALE 64 2h 15m - - - - X -
26 0 MALE 52 4h 40m - - - - X -
27 0 MALE 79 7h 45m 7.1 - - - - -
28 0 MALE 52 3h 30m 8 - - - - -
29 0 MALE 51 4h 6.5 - - - - -
30 0 MALE 75 9h 6.6 - - - - -
31 0 MALE 58 4h 7.7 - - - - -
32 0 MALE 82 11h 6.6 - - - - -
33 0 MALE 73 7h 7.2 - - - - -
34 0 MALE 73 5h 30m 7 - - - - -
35 iPD MALE 57 11h 8.7 8.3 X X - -
36 iPD FEMALE 54 11h 10m 8.2 - X X - -
37 iPD FEMALE 70 10h 50m - 8.7 - X - -
38 iPD MALE 66 5h 7.3 7.3 X X - -
39 iPD MALE 72 5h 7.7 - - - - -
40 iPD MALE 57 19h 7.6 7 X X - -
41 iPD MALE 76 4h 30m 7.7 7.9 X X - -
42 iPD MALE 68 4h 45m 7.3 8.5 X X - -
43 iPD MALE 79 9h 15m 7.2 - X X - -
44 iPD MALE 69 5h 55m 6.4 7.6 X X - -
45 iPD MALE 68 9h 20m 6.9 - - - - -
46 iPD MALE 77 12h 6.9 - - - - -
47 iPD FEMALE 84 4h 30m 7.8 - - - - -
48 iPD MALE 69 15 h 05 m 8.1 - - X - -
49 iPD MALE 78 10h 45m 7.3 - - - - -
50 PD FEMALE 70 4h 30m 8.5 - X - X -
51 PD FEMALE 77 3h 30m 6.8 - X - - -
52 PD FEMALE 81 6h 30m 8.3 - X - - -
53 PD FEMALE 69 4h 30 m 8 - X - - -
54 PD FEMALE 79 3h 30m 8 - X - X -
55 PD MALE 78 13h 30m 6.7 - - - - -
56 PD MALE 83 14h 7.7 - - - - -
57 PD FEMALE 77 7h 30m 7.1 - - - X -
58 PD FEMALE 84 4h 7.3 6.9 - - X X
59 PD MALE 76 12h 6.5 - - - X -
60 PD MALE 78 13h 30m 7.7 - - - X -
61 PD MALE 83 14h 7 - - - X -
62 PD MALE 76 21h 45m 7.2 6.8 - - X X
63 PD MALE 79 4h 30m 6.8 7.5 - - X X
64 PD MALE 77 7h 30m 6.7 7 - - X X
65 PD FEMALE 78 4h 30m - 6.6 - X - X
66 PD FEMALE 79 1h 30m - 7.2 - X - X
67 PD MALE 76 4h - 6.6 - X - X
68 PD MALE 84 4h - 7.7 - X - X
69 PD MALE 87 7h 30m - 7.5 - X - X
70 PDD MALE 80 7h 30m 7.2 6.6 X X X X
71 PDD MALE 82 16h 30m 7.3 6.7 X X X X
72 PDD MALE 76 9h 40m 6.8 6.4 X X X X
73 PDD MALE 84 16h 30m 7.1 7.4 X X X X  
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Table II: Abbreviated and full names of genes, and TaqMan probes used for the study 









GUS-B β-glucuronidase Hs00939627_m1 
  
XPNPEP1 X-prolyl aminopeptidase (aminopeptidase P) 1 Hs00958026_m1 
Mitochondrial 
subunits Complex I 
 
NDUFA2 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 2, 8kDa Hs00159575_m1 
    NDUFA7 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 7, 14.5kDa Hs01561430_m1 
    NDUFA10 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 10, 42kDa Hs01071117_m1 
    NDUFB3 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 3, 12kDa Hs00427185_m1 
    NDUFB7 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 7, 18kDa Hs00188142_m1 
    NDUFB10 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 10, 22kDa Hs00605903_m1 
    NDUFS7 NADH dehydrogenase (ubiquinone) Fe-S protein 7, 20kDa (NADH-coenzyme Q reductase) Hs00257018_m1 
    NDUFS8 NADH dehydrogenase (ubiquinone) Fe-S protein 8, 23kDa (NADH-coenzyme Q reductase) Hs00159597_m1 
  Complex II SDHB succinate dehydrogenase complex, subunit B, iron sulfur (Ip) Hs00268117_m1 
  Complex III UQCRB ubiquinol-cytochrome c reductase binding protein Hs00559884_m1 
    UQCR11 ubiquinol-cytochrome c reductase, complex III subunit XI Hs00907747_m1 
  Complex IV COX7A2L cytochrome c oxidase subunit VIIa polypeptide 2 like Hs00190880_m1 
    COX7C cytochrome c oxidase subunit VIIc Hs01595220_g1 
  Complex V ATP5D ATP synthase, H+ transporting, mitochondrial F1 complex, delta subunit Hs00961521_m1 
    ATP5G2 ATP synthase, H+ transporting, mitochondrial Fo complex, subunit C2 (subunit 9) Hs01096582_m1 
    ATP5H ATP synthase, H+ transporting, mitochondrial Fo complex, subunit d Hs01046892_gH 
    ATP5L ATP synthase, H+ transporting, mitochondrial Fo complex, subunit G Hs00538946_g1 
    ATP5O ATP synthase, H+ transporting, mitochondrial F1 complex, O subunit Hs00426889_m1 
Energy metabolism-related 
enzymes ATP2B3 ATPase, Ca++ transporting, plasma membrane 3 Hs00222625_m1 
    ATP2B4 ATPase, Ca++ transporting, plasma membrane 4 Hs00608066_m1 
    ATP4A ATPase, H+/K+ exchanging, alpha polypeptide Hs00167575_m1 
    ATP6V0A1 ATPase, H+ transporting, lysosomal V0 subunit a1 Hs00193110_m1 
    ATP6V0B ATPase, H+ transporting, lysosomal 21kDa, V0 subunit b Hs01072388_m1 
    ATP6V1H ATPase, H+ transporting, lysosomal 50/57kDa, V1 subunit H Hs00977530_m1 
    FAM82A2 family with sequence similarity 82, member A2 Hs00216746_m1 
    LHPP phospholysine phosphohistidine inorganic pyrophosphate phosphatase Hs00383379_m1 
    SLC6A6 solute carrier family 6 (neurotransmitter transporter, taurine), member 6 Hs00161778_m1 
    SLC25A31 solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 31 Hs00229864_m1 
    TOMM40 translocase of outer mitochondrial membrane 40 homolog (yeast) Hs01587378_mH 
    ZNF642 zinc finger protein 642 Hs01372953_m1 
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Table III: Summary of mRNA expression levels of genes encoding subunits of the 
mitochondrial complexes and energy metabolism-related enzymes in the frontal cortex 
in MA, iPD, PD and PDD. Up-regulated gene expression occurs in PD 5-6 when 
compared with MA and PD 3-4. However, important decay in gene expression is 
observed in PDD when compared with PD.  Student’s T-test *p < 0.05, **p < 0.01, ***p 




MA vs PD 3-4 MA vs PD 5-6 PD 3-4 vs PD 5-6 MA vs PDD PD 3-4 vs PDD PD 5-6 vs PDD
Mitochondrial elements
Complex I NDUFA2 - - ↑* - - -
NDUFA7 - ↑** ↑** - - ↓**
NDUFA10 - ↑** ↑* - - ↓*
NDUFB3 ↓* - ↑** - - -
NDUFB7 - ↑* - - - ↓*
NDUFB10 - ↑* - - - ↓*
NDUFS8 - ↑* - - - ↓*
Complex II SDHB - ↑* - ↓* - ↓*
Complex III UQCRB - - - - - ↓*
UQCR11 - ↑* - - - -
Complex IV COX7A2L - ↑* - - - ↓**
COX7C - - - ↓* - ↓*
Complex V ATP5G2 - ↑* ↑* ↓* - ↓**
ATP5H ↓** - ↑** - - -
ATP5L - - ↑* - - ↓**
ATP5O - - - - - ↓*
Energy metabolism-related molecules
ATP2B4 ↓* - ↑** ↓* - ↓*
ATP4A ↑* - ↑** - - -
ATP6V0A1 - - ↑** - - ↓*
ATP6V0B ↓** - ↑** ↓** - ↓*
ATP6V1H - - - - - ↓**
FAM82A2 - - - ↓* - -
LHPP - - - ↓* - -
TOMM40 ↓* - ↑* - - -
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Table IV: Summary of mRNA expression levels of genes encoding subunits of the 
mitochondrial complexes and energy metabolism-related enzymes in the angular gyrus 
in MA, iPD, PD and PDD. Up-regulated gene expression occurs in PD 3-4 when 
compared with MA. However, important decay in gene expression is observed in PD 5-
6 and PDD when compared with PD 3-4.  Student’s T-test *p < 0.05, **p < 0.01, ***p < 





MA vs PD 3-4 MA vs PD 5-6 PD 3-4 vs PD 5-6 MA vs PDD PD 3-4 vs PDD PD 5-6 vs PDD
Mitochondrial elements
Complex I NDUFA2 - - - - ↓* -
NDUFA7 ↑** - ↓*** - ↓** -
NDUFA10 ↑* ↑* - - ↓* -
NDUFB3 - - - - - -
NDUFB7 - - - - - -
NDUFB10 ↑* - ↓** - ↓** -
NDUFS7 ↑* - ↓** - ↓** -
NDUFS8 - - ↓* - - -
Complex II SDHB - - - - ↓* -
Complex III UQCRB ↑* - - - - -
UQCR11 ↑* - - - ↓* -
Complex IV COX7A2L ↑* - ↓** - ↓** ↓**
COX7C - - - - - -
Complex V ATP5D ↑* - - - - -
ATP5G2 ↑* - - - ↓* -
ATP5H - - - - - -
ATP5L - - - - - -
ATP5O - - - - ↓* -
Energy metabolism-related molecules
ATP2B3 - - - - - -
ATP2B4 - - - ↓* ↓* ↓***
ATP4A - - - - - -
ATP6V0A1 - - - - - -
ATP6V0B ↑** - ↓** - ↓* -
ATP6V1H ↑*** - ↓*** - ↓*** ↓**
FAM82A2 - - - ↓* - ↓**
LHPP - - - ↓* - ↓**
SLC6A6 - - - - ↓* -
SLC25A31 - - - - - -
TOMM40 - - - - - -
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Figure 1: Representative western blots of NDUFA7, NDUFA10, NDUFB10, NDUFS8 
and COX7A2L protein expression in frontal cortex area 8 (A) and the angular gyrus (B) 
in MA, iPD, PD and PDD. Expression values are normalized with β-actin and VDAC. 
Graphs represent the total number of cases examined (see Table I). Data are 
represented as mean ± SEM. Student’s T-test: *p < 0.05, **p < 0.01, ***p < 0.001, 
significant differences in iPD, PD or PDD when compared with MA cases. #p < 0.05, ##p 
< 0.01, ###p < 0.001, differences between PD or PDD versus iPD cases. $p < 0.05, $$p < 
0.01, $$$p < 0.001, observed differences when comparing PD to PDD individuals. a No 
Gaussian distribution (Mann Whitney test). 
 
Figure 2: Representative western blots of MT-ND1 protein expression in frontal cortex 
area 8 and angular gyrus in MA, iPD, PD and PDD. Expression values are normalized 
with β-actin and VDAC. Graphs represent the total number of cases examined (see 
Table I). Data are represented as mean ± SEM. Student’s T-test: *p < 0.05, **p < 0.01, 
***p < 0.001. 
  
Figure 3: Enzyme activities of complexes I, II, III, IV and V normalized with citrate 
synthase activity in frontal cortex (A) and angular gyrus (B) in MA and PD. Activity of 
complex I, II and V is preserved in the frontal cortex in PD, whereas activity of complex 
II is decreased and activity of complex IV augmented. Enzymatic activities of complex I, 
II, IV and V are preserved in the angular gyrus but complex III activity is decreased in 
PD when compared with MA. Student’s T-test *p < 0.05, **p < 0.01, ***p < 0.001. a No 
Gaussian distribution (Mann Whitney test) *p < 0.05, **p < 0.01, ***p < 0.001. 
 
Figure 4: Enzyme activities of complexes I, II, III, IV and V normalized with citrate 
synthase activity in frontal cortex (A) and angular gyrus (B) in middle-aged (MA) and 
PDD. Significantly decreased activity of complex I, II, III and IV is found in frontal cortex 
and angular gyrus (p-values between 0.05 and 0.01) in PDD when compared with MA. 
Student’s T-test *p < 0.05, **p < 0.01, ***p < 0.001. a No Gaussian distribution (Mann 
Whitney test) *p < 0.05, **p < 0.01, ***p < 0.001.  
 
Figure 5: Western blot of mitochondrial-enriched fractions in frontal cortex (FC) in MA 
cases and PD. A) No differences in protein expression levels of monomeric α-synuclein 
17 kDa are seen between MA and PD. However, significant expression of oligomeric α-
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synuclein of 37 kDa and 50 kDa is found in PD when compared with MA. β-actin is 
used as a marker of protein loading, and ATP5A as a mitochondrial marker. B) 
Increased levels of neuroketal (NKT) protein adducts in mitochondrial-enriched 
fractions in PD when compared with MA cases. C) No significant differences of N-
Tyrosine levels are seen between the two groups. Student’s T-test *p < 0.05, **p < 
0.01.  
  
Page 31 of 41
Brain Pathology Editorial Office, Blackwell Publishing, Oxford, UK
Brain Pathology




Table I: mRNA expression levels of genes encoding subunits of the mitochondrial 
complexes and energy metabolism-related enzymes in the frontal cortex MA, iPD, PD 
and PDD as determined with TaqMan PCR assays using GUS-β for normalization. 
Note marked differences in gene expression between MA and PD, mostly 
characterized by up-regulated gene expression, and between PD and PDD, with 
dramatic down-regulation of the majority of mitochondrial subunits assessed. Subunits 
are not limited to a single complex but members of all the mitochondrial complexes are 
affected in PDD. A more complex scenario occurs in the expression of other energy 
metabolism-related enzymes at different stages of disease. However, important decay 
in gene expression is also observed in PDD when compared with PD.  Student’s T-test 
*p < 0.05, **p < 0.01, ***p < 0.001. a No Gaussian distribution (Mann Whitney test *p < 
0.05, **p < 0.01, ***p < 0.001. 
 
MA iPD PD PDD MAvsiPD MAvsPD iPDvsPD MAvsPDD iPDvsPD PDvsPDD
Mitochondrial elements
Complex I NDUFA2 1.08 ± 0.46 0.75 ± 0.49 1.20 ± 0.44 0.60 ± 0.36 - - ↑* - - -
NDUFA7 1.08 ±  0.38ª 0.94 ± 0.56 1.65 ± 0.44 0.62 ± 0.37 - ↑** ↑** - - ↓**
NDUFA10 1.07 ± 0.36 1.09 ± 0.52 1.68 ± 0.53ª 0.81 ± 0.43 - ↑** ↑* - - ↓*
NDUFB3 1.08 ± 0.42 0.67 ± 0.47 1.33 ± 0.46 0.95 ± 0.45 ↓* - ↑** - - -
NDUFB7 1.07 ± 0.40 1.15 ± 0.63 1.67 ± 0.76 0.60 ± 0.29 - ↑* - - - ↓*
NDUFB10 1.10 ± 0.45 1.14 ± 0.74 1.58 ± 0.42 0.74 ± 0.47 - ↑* - - - ↓*
NDUFS7 1.02 ± 0.19 0.98 ± 0.30 1.17 ± 0.41ª 0.75 ± 0.33 - - - - - -
NDUFS8 1.10 ± 0.45 1.16 ± 0.62 1.58 ± 0.49 0.82 ± 0.37 - ↑* - - - ↓*
Complex II SDHB 1.04 ± 0.30 1.05 ± 0.67 1.40 ± 0.46 0.49 ± 0.43 - ↑* - ↓* - ↓*
Complex III UQCRB 1.07 ± 0.41 0.94 ± 0.66 1.33 ± 0.49 0.55 ± 0.42 - - - - - ↓*
UQCR11 1.04 ± 0.31 1.00 ± 0.70 1.44 ± 0.51 0.73 ± 0.40 - ↑* - - - -
Complex IV COX7A2L 1.17 ± 0.53 1.19 ± 0.87 1.76 ± 0.49 0.70 ± 0.44 - ↑* - - - ↓**
COX7C 1.10 ± 0.46 0.77 ± 0.59 1.12 ± 0.42 0.50 ± 0.31 - - - ↓* - ↓*
Complex V ATP5D 1.12 ± 0.55 0.91 ± 0.63 1.26 ± 0.62 0.84 ± 0.47 - - - - - -
ATP5G2 1.04 ± 0.28 1.02 ± 0.41 1.37 ± 0.31ª 0.60 ± 0.43 - ↑* ↑* ↓* - ↓**
ATP5H 1.08 ± 0.43 0.64 ± 0.34 1.14 ± 0.41 0.59 ± 0.40 ↓** - ↑** - - -
ATP5L 1.12 ± 0.66 1.24 ± 0.72 1.66 ± 0.44 0.66 ± 0.36 - - ↑* - - ↓**
ATP5O 1.06 ± 0.40 0.91 ± 0.52 1.19 ± 0.37 0.60 ± 0.39 - - - - - ↓*
Energy metabolism-related molecules
ATP2B3 1.09 ± 0.43 0.85 ± 0.62 1.30 ± 0.58 0.76 ± 0.49 - - - - - -
ATP2B4 1.06 ± 0.35 0.70 ± 0.39 1.39 ± 0.55 0.59 ± 0.32 ↓* - ↑** ↓* - ↓*
ATP4A 1.14 ± 0.78 1.94 ± 0.99 3.04 ± 2.15 0.68 ± 0.24 ↑* - ↑** - - -
ATP6V0A1 1.10 ± 0.44 0.82 ± 0.42 1.52 ± 0.54 0.65 ± 0.38 - - ↑** - - ↓*
ATP6V0B 1.10 ± 0.14 0.81 ± 0.20 1.52 ± 0.56 0.72 ± 0.42 ↓** - ↑** ↓** - ↓*
ATP6V1H 1.33 ± 0.73 1.34 ± 1.09 1.98 ± 0.72 0.50 ± 0.40 - - - - - ↓**
FAM82A2 1.07 ± 0.38 1.05 ± 0.43 1.42 ± 0.70 0.51 ± 0.25 - - - ↓* - -
LHPP 1.04 ± 0.31ª 1.06 ± 0.43 1.15 ± 0.52 0.60 ± 0.23 - - - ↓* - -
SLC6A6 1.05 ± 0.45 1.38 ± 0.48 1.15 ± 0.60 0.90 ± 0.31 - - - - - -
SLC25A31 1.11 ± 0.51 1.06 ± 0.49 1.04 ± 0.39 0.73 ± 0.24 - - - - - -
TOMM40 1.09 ± 0.45 0.67 ± 0.36 1.04 ± 0.34 0.60 ± 0.45 ↓* - ↑* - - -
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Supplementary Table II: mRNA expression levels of genes encoding subunits of the 
mitochondrial complexes and energy metabolism-related enzymes in the angular gyrus 
in MA, iPD, PD and PDD as determined with TaqMan PCR assays using GUS-β for 
normalization. A transient increase in the mRNA expression of several genes encoding 
subunits of complexes I, IV and V, and encoding energy metabolism-related enzymes 
is observed in iPD when compared with MA. Although NDUFA10 mRNA expression 
remains increased in PD when compared with MA, a significant decrease of several 
genes is found in PD when compared with iPD. A dramatic decrease is found in PDD 
when compared with iPD. COX7A2L, ATP2B4, ATP6V1H and FAM82A2 mRNA 
expression is significantly decreased in PDD when compared with PD. Student’s T-test 
*p < 0.05, **p < 0.01, ***p < 0.001. a No Gaussian distribution (Mann Whitney test) *p < 
0.05, **p < 0.01, ***p < 0.001. 
MA iPD PD PDD MAvsiPD MAvsPD iPDvsPD MAvsPDD iPDvsPD PDvsPDD
Mitochondrial elements
Complex I NDUFA2 1.07 ± 0.40 1.34 ± 0.48 1.01 ± 0.24 0.62 ± 0.36 - - - - ↓* -
NDUFA7 1.06 ± 0.38 2.04 ± 0.66 1.02 ± 0.16 0.69 ± 0.50 ↑** - ↓*** - ↓** -
NDUFA10 1.14 ± 0.56 1.85 ± 0.53 1.98 ± 0.81 0.89 ± 0.49 ↑* ↑* - - ↓* -
NDUFB3 1.10 ± 0.51 1.59 ± 0.74 1.03 ± 0.28 0.96 ± 0.37 - - - - - -
NDUFB7 1.05 ± 0.34 1.30 ± 0.46 1.01 ± 0.17 0.74 ± 0.42 - - - - - -
NDUFB10 1.39 ± 0.86 2.20 ± 0.65 1.36 ± 0.29 0.88 ± 0.60 ↑* - ↓** - ↓** -
NDUFS7 1.11 ± 0.46 1.62 ± 0.42 1.08 ± 0.12 0.83 ± 0.30 ↑* - ↓** - ↓** -
NDUFS8 1.03 ± 0.24 1.35 ± 0.45 0.97 ± 0.07 0.81 ± 0.24 - - ↓* - - -
Complex II SDHB 1.09 ± 0.46 1.55 ± 0.66 1.05 ± 0.23 0.56 ± 0.34 - - - - ↓* -
Complex III UQCRB 1.06 ± 0.37 1.71 ± 0.79 1.16 ± 0.20 0.85 ± 0.48 ↑* - - - - -
UQCR11 1.10 ± 0.49 1.70 ± 0.66 1.08 ± 0.19 0.69 ± 0.60 ↑* - - - ↓* -
Complex IV COX7A2L 1.17 ± 0.73 2.06 ± 0.63 1.35 ± 0.16 0.71 ± 0.40 ↑* - ↓** - ↓** ↓**
COX7C 1.13 ± 0.58 1.72 ± 0.71 1.03 ± 0.25 0.72 ± 0.50 - - - - - -
Complex V ATP5D 1.06 ± 0.39 1.61 ± 0.55 1.15 ± 0.22 0.89 ± 0.49 ↑* - - - - -
ATP5G2 1.01 ± 0.19 1.25 ± 0.20 1.06 ± 0.30 0.79 ± 0.62 ↑* - - - ↓* -
ATP5H 1.05 ± 0.35 1.23 ± 0.47 1.00 ± 0.35 0.77 ± 0.56 - - - - - -
ATP5L 1.08 ± 0.45 1.33 ± 0.47 1.08 ± 0.32 0.73 ± 0.44 - - - - - -
ATP5O 1.12 ± 0.56 1.68 ± 0.62 1.09 ± 0.20 0.68 ± 0.44 - - - - ↓* -
Energy metabolism-related molecules
ATP2B3 1.04 ± 0.31 1.17 ± 0.45 1.04 ± 0.50 0.94 ± 0.68 - - - - - -
ATP2B4 1.05 ± 0.34 0.82 ± 0.27 0.86 ± 0.03 0.46 ± 0.16 - - - ↓* ↓* ↓***
ATP4A 1.16 ± 0.76ª 1.02 ± 0.78 0.92 ± 0.07 0.83 ± 0.24 - - - - - -
ATP6V0A1 1.04 ± 0.32 1.08 ± 0.38 1.03 ± 0.32 0.73 ± 0.39 - - - - - -
ATP6V0B 1.11 ± 0.49 2.32 ± 1.01 1.30 ± 0.30 0.82 ± 0.41 ↑** - ↓** - ↓* -
ATP6V1H 1.28 ± 0.84 3.09 ± 0.72 1.54 ± 0.46 0.58 ± 0.43 ↑*** - ↓*** - ↓*** ↓**
FAM82A2 1.02 ± 0.24 1.36 ± 0.90 1.03 ± 0.18 0.66 ± 0.32 - - - ↓* - ↓**
LHPP 1.03 ± 0.26 1.04 ± 0.39 1.23 ± 0.26 0.62 ± 0.20 - - - ↓* - ↓**
SLC6A6 1.04 ± 0.31 1.19 ± 0.24 1.10 ± 0.58 0.81 ± 0.25 - - - - ↓* -
SLC25A31 1.17 ± 0.66 1.27 ± 0.82 1.22 ± 0.21 0.88 ± 0.43 - - - - - -
TOMM40 1.17 ± 0.75 1.72 ± 0.75 0.93 ± 0.16 0.70 ± 0.64 - - - - - -
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Figure 1: Representative western blots of NDUFA7, NDUFA10, NDUFB10, NDUFS8 and COX7A2L protein 
expression in frontal cortex area 8 (A) and the angular gyrus (B) in MA, iPD, PD and PDD. Expression values 
are normalized with β-actin and VDAC. Graphs represent the total number of cases examined (see Table I). 
Data are represented as mean ± SEM. Student’s T-test: *p < 0.05, **p < 0.01, ***p < 0.001, significant 
differences in iPD, PD or PDD when compared with MA cases. #p < 0.05, ##p < 0.01, ###p < 0.001, 
differences between PD or PDD versus iPD cases. $p < 0.05, $$p < 0.01, $$$p < 0.001, observed 
differences when comparing PD to PDD individuals. a No Gaussian distribution (Mann Whitney test).  
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Figure 2: Representative western blots of MT-ND1 protein expression in frontal cortex area 8 and angular 
gyrus in MA, iPD, PD and PDD. Expression values are normalized with β-actin and VDAC. Graphs represent 
the total number of cases examined (see Table I). Data are represented as mean ± SEM. Student’s T-test: 
*p < 0.05, **p < 0.01, ***p < 0.001.  
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Figure 3: Enzyme activities of complexes I, II, III, IV and V normalized with citrate synthase activity in 
frontal cortex (A) in MA and PD. Activity of complex I, II and V is preserved in the frontal cortex in PD, 
whereas activity of complex II is decreased and activity of complex IV augmented. Enzymatic activities of 
complex I, II, IV and V are preserved in the angular gyrus but complex III activity is decreased in PD when 
compared with MA. Student’s T-test *p < 0.05, **p < 0.01, ***p < 0.001. a No Gaussian distribution 
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Figure 3: Enzyme activities of complexes I, II, III, IV and V normalized with citrate synthase activity in 
angular gyrus (B) in MA and PD. Activity of complex I, II and V is preserved in the frontal cortex in PD, 
whereas activity of complex II is decreased and activity of complex IV augmented. Enzymatic activities of 
complex I, II, IV and V are preserved in the angular gyrus but complex III activity is decreased in PD when 
compared with MA. Student’s T-test *p < 0.05, **p < 0.01, ***p < 0.001. a No Gaussian distribution 
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Figure 4: Enzyme activities of complexes I, II, III, IV and V normalized with citrate synthase activity in 
frontal cortex (A) in middle-aged (MA) and PDD. Significantly decreased activity of complex I, II, III and IV 
is found in frontal cortex and angular gyrus (p-values between 0.05 and 0.01) in PDD when compared with 
MA. Student’s T-test *p < 0.05, **p < 0.01, ***p < 0.001. a No Gaussian distribution (Mann Whitney test) 
*p < 0.05, **p < 0.01, ***p < 0.001.  
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Figure 4: Enzyme activities of complexes I, II, III, IV and V normalized with citrate synthase activity in 
angular gyrus (B) in middle-aged (MA) and PDD. Significantly decreased activity of complex I, II, III and IV 
is found in frontal cortex and angular gyrus (p-values between 0.05 and 0.01) in PDD when compared with 
MA. Student’s T-test *p < 0.05, **p < 0.01, ***p < 0.001. a No Gaussian distribution (Mann Whitney test) 
*p < 0.05, **p < 0.01, ***p < 0.001.  
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Figure 5: Western blot of mitochondrial-enriched fractions in frontal cortex (FC) in MA cases and PD. A) No 
differences in protein expression levels of monomeric α-synuclein 17 kDa are seen between MA and PD. 
However, significant expression of oligomeric α-synuclein of 37 kDa and 50 kDa is found in PD when 
compared with MA. β-actin is used as a marker of protein loading, and ATP5A as a mitochondrial marker. B) 
Increased levels of neuroketal (NKT) protein adducts in mitochondrial-enriched fractions in PD when 
compared with MA cases. C) No significant differences of N-Tyrosine levels are seen between the two 
groups. Student’s T-test *p < 0.05, **p < 0.01.  
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